Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

April 6, 2022

Hopkinton cellular therapy company acquires California firm

Hopkinton-based Isto Biologics, a biologic and cellular therapy company in the orthopedic space, has acquired Los Angeles-based TheraCell, Inc.

The acquisition will strengthen Isto’s solutions for surgical and clinical care procedures within spine, orthopedics, and sports medicine, according to a press release from Isto.

“TheraCell has excelled in developing advanced bone integrating, anchoring, and bridging technologies for spinal repair for over a decade,” Isto CEO Don Brown said in the release.

Isto Biologics products include a platelet separator and bone-growth products. Theracell’s TheraFuze DBF technology will become part of Isto Biologics’ Influx bone-growth line, according to the release.

Isto Biologics is a portfolio company of St. Louis-based Thompson Street Capital Partners.

Financial details of the acquisition were not released.

Sign up for Enews

WBJ Web Partners

0 Comments

Register for free to read more articles.

Register Now

Already have an online account? Login

To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy

Allow Cookies